论文部分内容阅读
目的:研究凋亡促进基因PDCD5在多发性骨髓瘤(MM)中的表达,分析其与抑凋亡基因BCL-2的相关性,初步探讨PDCD5在MM发病机制中的作用。方法:采用免疫组织化学染色、流式细胞检测术和逆转录-聚合酶链反应(RT-PCR)方法测定MM患者组和对照组骨髓单个核细胞PDCD5和BCL-2蛋白和mRNA的表达,同时对两者进行相关性分析。结果:免疫组织化学结果显示,PDCD5蛋白阳性细胞率MM组为(34.75±6.49)%,对照组为(52.98±5.84)%;PDCD5染色强度指数(SII)MM组为281.16±75.33,对照组为462.84±39.77;BCL-2蛋白阳性细胞率MM组(29.97±5.57)%,对照组(5.56±1.95)%;BCL-2蛋白SII在MM组为224.94±57.72,对照组为27.84±9.75;以上指标两组比较差异均有统计学意义(P<0.05)。流式细胞技术检测,骨髓浆细胞中PDCD5蛋白阳性率MM组(78.11±21.63)%,对照组(89.46±9.98)%;蛋白平均荧光强度MM组为61.73±11.04,对照组为353.04±123.26;以上两组比较差异均有统计学意义(P<0.05)。RT-PCR检测,PDCD5mRNA的相对表达水平MM组为0.33±0.07,对照组为0.53±0.05;BCL-2mRNA的相对表达水平MM组为0.33±0.08,对照组为0.12±0.02;以上两组比较差异均有统计学意义(P<0.05)。PDCD5与BCL-2表达相关性研究结果,PDCD5与BCL-2蛋白阳性细胞率表达呈负相关(r=-0.86,P<0.05);PDCD5与BCL-2mRNA相对表达水平呈负相关(r=-0.90,P<0.05)。结论:MM患者骨髓单个核细胞PDCD5蛋白和mRNA表达下调;BCL-2蛋白和mRNA表达上调;PDCD5与BCL-2蛋白阳性细胞率和mRNA表达均呈负相关。
OBJECTIVE: To study the expression of PDCD5 in multiple myeloma (MM) and analyze its relationship with the anti-apoptotic gene BCL-2 and to explore the role of PDCD5 in the pathogenesis of MM. Methods: The expressions of PDCD5 and BCL-2 protein and mRNA in bone marrow mononuclear cells of MM patients and controls were determined by immunohistochemical staining, flow cytometry and reverse transcription-polymerase chain reaction (RT-PCR) Correlation analysis of the two. Results: The positive rate of PDCD5 protein in MM group was (34.75 ± 6.49)% in control group and (52.98 ± 5.84)% in immunostaining group, and 281.16 ± 75.33 in PDCD5 staining intensity group (SII) 462.84 ± 39.77; The positive rate of BCL-2 protein was 29.97 ± 5.57% in MM group and 5.56 ± 1.95% in control group. The SII of BCL-2 protein was 224.94 ± 57.72 in MM group and 27.84 ± 9.75 in control group There was significant difference between the two groups (P <0.05). Flow cytometry showed that the positive rate of PDCD5 protein in bone marrow plasma cells was (78.11 ± 21.63)% in MM group and 89.46 ± 9.98% in control group (P <0.05). The average fluorescence intensity of protein group was 61.73 ± 11.04 in MM group and 353.04 ± 123.26 in control group The difference between the above two groups was statistically significant (P <0.05). The relative expression level of PDCD5mRNA in MM group was 0.33 ± 0.07, in control group was 0.53 ± 0.05; The relative expression level of BCL-2 mRNA in MM group was 0.33 ± 0.08, and the control group was 0.12 ± 0.02 All were statistically significant (P <0.05). There was a negative correlation between the expression of PDCD5 and BCL-2 (r = -0.86, P <0.05), the relative expression of PDCD5 and BCL-2 mRNA (r = 0.90, P <0.05). CONCLUSION: The expression of PDCD5 protein and mRNA in bone marrow mononuclear cells of MM patients is down-regulated while the protein and mRNA expression of BCL-2 is up-regulated. The positive rates of PDCD5 and BCL-2 protein are negatively correlated.